Topiramate Capsule, Extended Release
Product Images NDC 0480-2356

7 FDA label images from Teva Pharmaceuticals, Inc. · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Topiramate (NDC 0480-2356). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Teva Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Structural Formula (Image 1)

Structural Formula (Image 1)
Chemical structure of Topiramate showing its molecular arrangement with carbon, oxygen, sulfur, nitrogen, and hydrogen atoms as part of the sulfamate substituted derivative. The structure highlights key functional groups including the cyclic sugar moiety and sulfamate group.*
FDA Label Image

1 (Image 2)

1 (Image 2)
A cumulative rate plot showing time to first seizure for Topiramate doses of 50 mg/day and 400 mg/day over approximately 500 days. The graph compares cumulative rates for two groups, with the x-axis representing time in days and the y-axis representing cumulative rates for time to first seizure. Statistical significance (p = 0.0002) is indicated.*
FDA Label Image

1 (Image 3)

1 (Image 3)
A bar chart showing the change from baseline to double-blind phase in average monthly migraine headache days in two studies. The x-axis lists placebo and three dosages of topiramate extended release capsules: 50 mg/day, 100 mg/day, and 200 mg/day. The y-axis measures change from baseline with negative values indicating improvement. Both studies show greater reduction in headache days with increasing doses of topiramate compared to placebo, with statistical significance indicated for higher doses.*
FDA Label Image

1 (Image 4)

1 (Image 4)
Label for Topiramate Extended-Release Capsules 200 mg by Teva Pharmaceuticals, Inc. The label indicates 30 capsules per container, intended for once-daily use. It includes storage instructions, manufacturing details, and a barcode on the right side.*
FDA Label Image

1 (Image 5)

1 (Image 5)
Label for Topiramate Extended-Release Capsules 50 mg from Teva Pharmaceuticals. The label indicates the product is for once daily use, contains 30 capsules, and instructs to swallow the capsule whole. It includes storage instructions, manufacturer details from Bulgaria, and a barcode.*
FDA Label Image

1 (Image 6)

1 (Image 6)
Topiramate Extended-Release Capsules 100 mg label by Teva Pharmaceuticals, Inc. The label indicates the product is for once-daily administration with 30 capsules per package. It includes storage instructions, usual dosage directions advising to see package insert, and manufacturing details noting production in Bulgaria for Teva Pharmaceuticals in New Jersey. The label features a barcode and NDC 0480-2358-56.*
FDA Label Image

1 (Image 7)

1 (Image 7)
Label for Topiramate Extended-release Capsules, 200 mg, by Teva Pharmaceuticals, Inc. The label states this DRUG FOR FURTHER PROCESSING is a once-daily extended-release capsule, with a package count of 30 capsules. It includes storage instructions and manufacturer information, specifying the capsules are manufactured in Bulgaria for Teva Pharmaceuticals.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.